4.5 Article

Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein

Journal

HEPATOLOGY RESEARCH
Volume 48, Issue 6, Pages 424-432

Publisher

WILEY
DOI: 10.1111/hepr.13046

Keywords

fibrosis; liver cirrhosis; Mac-2BP; non-alcoholic fatty liver disease; WFA(+)-Mac-2BP

Funding

  1. Grants-in-Aid for Scientific Research [15K06810, 17K08936] Funding Source: KAKEN

Ask authors/readers for more resources

Aim: Serum Mac-2 binding protein (M2BP) and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP) are used to estimate the liver fibrosis stage in chronic liver diseases. However, few head-to-head studies have been carried out to compare the two biomarkers in non-alcoholic fatty liver disease (NAFLD). Methods: Serum M2BP and WFA(+)-M2BP levels were compared against clinical characteristics and liver histological manifestations in the same samples collected from 213 biopsy-proven NAFLD patients. Results: Median levels (range) of M2BP and WFA(+)-M2BP were 1.58 (0.70-7.75) pg/mL and 0.85 (0.22-11.32) cut-off index (COI), respectively. Fibrosis stages 1, 2, 3, and 4 were determined in 136, 37, 17, and 23 patients, respectively. Median levels of both biomarkers increased stepwise with fibrosis progression. The M2BP and WFA(+)-M2BP levels showed a significant positive correlation (r = 0.643, P = 2.91 x 10(-26)), but a marked discrepancy between both biomarkers was noted in five stage 4 and three stage 1 patients, who had high WFA(+)-M2BP but relatively low M2BP levels. Most of these outliers had findings suggestive of more advanced fibrosis. For diagnosing any fibrosis severity, WFA(+)-M2BP had greater area under the receiver operating characteristic curve (AUC) and predictive accuracy than M2BP. Among eight fibrosis markers/indices, WFA(+)-M2BP yielded the second highest AUC (0.832) and the highest predictive accuracy (82.2%) to diagnose cirrhosis. In addition, WFA(+)-M2BP showed the second highest predictive accuracy to diagnose severe fibrosis (78.4%) and significant fibrosis (76.1%). Conclusion: This head-to-head comparison suggests that WFA(+)-M2BP is superior to M2BP for distinguishing liver fibrosis stages in NAFLD patients. A marked discrepancy between the two biomarkers may be indicative of advanced NAFLD (UMIN000023286).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Postprandial Hyperchylomicronemia and Thin-Cap Fibroatheroma in Nonculprit Lesions: A Multivessel Optical Coherence Tomography Study

Osamu Kurihara, Fumitaka Okajima, Masamichi Takano, Katsuhito Kato, Ryo Munakata, Daisuke Murakami, Yasushi Miyauchi, Naoya Emoto, Hitoshi Sugihara, Yoshihiko Seino, Wataru Shimizu

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)

Meeting Abstract Peripheral Vascular Disease

POSTPRANDIAL HYPERCHYLOMICRONEMIA AND THIN-CAP FIBROATHEROMA IN NON-CULPRIT LESIONS: A MULTIVESSEL OPTICAL COHERENCE TOMOGRAPHY STUDY

Fumitaka Okajima, Osamu Kurihara, Masamichi Takano, Hitoshi Sugihara, Naoya Emoto

ATHEROSCLEROSIS SUPPLEMENTS (2018)

Article Endocrinology & Metabolism

Basal-Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study

Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto

DIABETES THERAPY (2018)

Article Endocrinology & Metabolism

Basal-Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study

Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto

DIABETES THERAPY (2018)

Article Gastroenterology & Hepatology

Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Mai Koeda, Yuji Yoshida, Tomomi Okubo, Ai Nakagawa, Norio Itokawa, Chisa Kondo, Katsuhisa Nakatsuka, Takushi Masu, Keizo Kato, Noritomo Shimada, Tsutomu Hatori, Naoya Emoto, Masayoshi Kage, Katsuhiko Iwakiri

DIGESTIVE AND LIVER DISEASE (2019)

Article Multidisciplinary Sciences

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadamichi Kawano, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Chiaki Kawamoto, Tsutomu Hatori, Naoya Emoto, Etsuko Iio, Yasuhito Tanake, Katsuhiko Iwakiri

PLOS ONE (2019)

Article Endocrinology & Metabolism

New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report

Hiroshi Yamada, Fumitaka Okajima, Takeshi Onda, Shunji Fujimori, Naoya Emoto, Hitoshi Sugihara

BMC ENDOCRINE DISORDERS (2020)

Article Endocrinology & Metabolism

Irrational Responses to Risk Preference Questionnaires by Patients with Diabetes with or without Retinopathy and Comparison with Those without Diabetes

Naoya Emoto, Akimi Soga, Izumi Fukuda, Kyoko Tanimura-Inagaki, Taro Harada, Hajime M. Koyano, Rei Goto, Hitoshi Sugihara

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)

Article Medicine, General & Internal

Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naive Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study

Fumitaka Okajima, Hitoshi Sugihara, Naoya Emoto

Summary: The study found that adding alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia in patients with type 2 diabetes.

JOURNAL OF NIPPON MEDICAL SCHOOL (2021)

Article Medicine, General & Internal

Risk Preferences, Rationality of Choices, and Willingness to Pay for Preventive Medicine in Patients with Graves' Thyrotoxicosis

Naoya Emoto, Mikiko Okazaki-Hada, Yuji Yamaguchi, Fumitaka Okajima, Rei Goto, Hitoshi Sugihara

Summary: The study found that risk preferences of patients with thyrotoxicosis remain relatively stable in hyperthyroid and euthyroid states, but willingness to pay for medical costs may change after normalization of thyroid function.

PATIENT PREFERENCE AND ADHERENCE (2021)

Article Multidisciplinary Sciences

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri

Summary: This study found that the severity of fibrosis in NAFLD is significantly and independently associated with high-risk CIMT. Non-invasive liver fibrosis markers and scoring systems may help estimate the risk of atherosclerosis progression in patients with NAFLD.

SCIENTIFIC REPORTS (2021)

Article Endocrinology & Metabolism

Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults

Kazuhiko Horiguchi, Yusaku Yoshida, Kenji Iwaku, Naoya Emoto, Toshihiko Kasahara, Junichiro Sato, Hiroki Shimura, Hisakazu Shindo, Satoru Suzuki, Hidekazu Nagano, Fumihiko Furuya, Noriko Makita, Fumihiko Matsumoto, Katsunori Manaka, Norisato Mitsutake, Megumi Miyakawa, Susumu Yokoya, Iwao Sugitani

Summary: Studies suggest that active surveillance is a safe and effective strategy for low-risk papillary thyroid microcarcinomas, preserving quality of life and reducing medical costs. However, high-risk cases should be closely monitored and surgery performed promptly during active surveillance.

ENDOCRINE JOURNAL (2021)

Article Endocrinology & Metabolism

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri

Summary: The study demonstrated that SGLT2-Is therapy can significantly improve liver inflammation, fatty changes, and fibrosis in patients with NAFLD, indicating their potential superiority to other oral hypoglycemic agents in addressing these conditions.

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)

Article Endocrinology & Metabolism

Painless destructive thyroiditis in a patient with resistance to thyroid hormone: a case report

Tomoko Nagamine, Jaeduk Yoshimura Noh, Naoya Emoto, Takahito Kogai, Akira Hishinuma, Fumitaka Okajima, Hitoshi Sugihara

THYROID RESEARCH (2019)

No Data Available